FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] The company is in the manufacturing and marketing of herbal products. However, the super profits shown by it for FY23 raise eyebrows and appear to be a window dressing. The asking price based on its super earnings appears to be lucrative at 8.4 P/E, but the sustainability of such performance going forward is a major concern. Though this issue is prima facie lucratively priced, there is no harm in skipping it. Read detail review...
Shelter Pharma Limited peer comparison with similar listed entities. () (As on March 31, 2022)
Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
---|---|---|---|---|
EPS Basic | ||||
Shelter Pharma Limited | 2.66 | 11.37 | 19.55 | 23.39 |
Dabur India Limited | 8.11 | 33.31 | 64.85 | 24.43 |
Emami Limited | 19.15 | 47.39 | 18.64 | 40.78 |
Notes:
Shelter Pharma IPO Reviews, analysis and views by popular members. Read Shelter Pharma Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 2 | 0 |
% | 0.00 | 0.00 | 100.00 | 0.00 |
Member | Review |
---|---|
Waseem |
Neutral Thanks for ur information |
Mr G |
Neutral since the company is more than a 50 years old and in the field of herbal remedies which is use by a mass after covid 19 so peolple can think on and can invest. August 8, 2023 6:45:16 PM |
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|